Drug-Induced Psychosis: How to Avoid Star Gazing in Schizophrenia Research by Looking at More Obvious Sources of Light
Alessandra Paparelli, Marta Di Forti, Paul D. Morrison, Robin Murray
Frontiers in Behavioral Neuroscience 2011 DOI: 10.3389/fnbeh.2011.00001 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | General (review of drug-induced psychosis) |
| Topics | Cannabis |
| Keywords | Psychosis Psychotomimetic Schizophrenia object-oriented programming Phencyclidine Substance abuse Population Disease Hallucinogen |
| Citations | 217 |
| Key findings | Liability to psychosis and schizophrenia is distributed continuously in the general population, and psychotomimetic drugs provide a key environmental link to understanding the disorder. |
Abstract
The prevalent view today is that schizophrenia is a syndrome rather than a specific disease. Liability to schizophrenia is highly heritable. It appears that multiple genetic and environmental factors operate together to push individuals over a threshold into expressing the characteristic clinical picture. One environmental factor which has been curiously neglected is the evidence that certain drugs can induce schizophrenia-like psychosis. In the last 60 years, improved understanding of the relationship between drug abuse and psychosis has contributed substantially to our modern view of the disorder suggesting that liability to psychosis in general, and to schizophrenia in particular, is distributed trough the general population in a similar continuous way to liability to medical disorders such as hypertension and diabetes. In this review we examine the main hypotheses resulting from the link observed between the most common psychotomimetic drugs (lysergic acid diethylamide, amphetamines, cannabis, phencyclidine) and schizophrenia.
Comparable studies
Other narrative reviews on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Causal association between cannabis and psychosis: examination of the evidence | 2004 | Review | |
| Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. General (historical and pharmacological review) | 2018 | Review | |
| Psychiatric effects of cannabis | 2001 | Review | |
| Beyond THC: The New Generation of Cannabinoid Designer Drugs | 2011 | Review | |
| Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug | 2006 | Review |
Citations in the library
Cited by 16
- “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology: Clinical and Experimental July 1, 2013
- Extended difficulties following the use of psychedelic drugs: A mixed methods study PLoS One October 24, 2023
- d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. Progress in Brain Research 2018
- From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders Journal of Neurochemistry September 14, 2021
- Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences Nordic Studies on Alcohol and Drugs February 1, 2021
and 11 more in the library
Cites 33
- Recent advances in the phencyclidine model of schizophrenia American Journal of Psychiatry October 1, 1991
- The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate British Journal of Pharmacology June 1, 1983
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- Study of a New Schizophrenomimetic Drug—Sernyl Archives of Neurology And Psychiatry March 1, 1959
- High-potency cannabis and the risk of psychosis The British Journal of Psychiatry November 30, 2009
and 28 more in the library